Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Receivables (2016 - 2026)

Champions Oncology has reported Receivables over the past 16 years, most recently at $18.2 million for Q1 2026.

  • Quarterly results put Receivables at $18.2 million for Q1 2026, down 15.52% from a year ago — trailing twelve months through Jan 2026 was $18.2 million (down 15.52% YoY), and the annual figure for FY2025 was $16.6 million, up 7.34%.
  • Receivables for Q1 2026 was $18.2 million at Champions Oncology, down from $18.7 million in the prior quarter.
  • Over the last five years, Receivables for CSBR hit a ceiling of $21.6 million in Q1 2025 and a floor of $10.3 million in Q3 2024.
  • Median Receivables over the past 5 years was $13.6 million (2022), compared with a mean of $14.7 million.
  • Biggest five-year swings in Receivables: dropped 22.43% in 2024 and later soared 75.71% in 2025.
  • Champions Oncology's Receivables stood at $13.3 million in 2022, then dropped by 12.12% to $11.7 million in 2023, then skyrocketed by 54.89% to $18.1 million in 2024, then rose by 3.23% to $18.7 million in 2025, then decreased by 2.61% to $18.2 million in 2026.
  • The last three reported values for Receivables were $18.2 million (Q1 2026), $18.7 million (Q4 2025), and $14.8 million (Q3 2025) per Business Quant data.